

Judith Absalon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2917812/publications.pdf>

Version: 2024-02-01

15
papers

17,104
citations

687220

13
h-index

940416

16
g-index

18
all docs

18
docs citations

18
times ranked

25422
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615. | 13.9 | 11,472 |
| 2 | Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450. | 13.9 | 2,107 |
| 3 | Phase II study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593. | 13.7 | 1,197 |
| 4 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773. | 13.9 | 1,090 |
| 5 | Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250. | 13.9 | 709 |
| 6 | Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 263-274. | 4.6 | 70 |
| 7 | A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. <i>New England Journal of Medicine</i> , 2017, 377, 2349-2362. | 13.9 | 57 |
| 8 | From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 461-477. | 2.0 | 46 |
| 9 | A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 673-682. | 1.1 | 41 |
| 10 | Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 548-554. | 1.1 | 39 |
| 11 | The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. <i>Vaccine</i> , 2018, 36, 6867-6874. | 1.7 | 29 |
| 12 | A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. <i>Vaccine</i> , 2016, 34, 1465-1471. | 1.7 | 26 |
| 13 | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12. | 1.4 | 14 |
| 14 | Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. <i>Vaccine</i> , 2022, 40, 1872-1878. | 1.7 | 2 |
| 15 | Safety of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in Young Adults: Results From a Phase 3 Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 1 |